发布求助
文献互助 智能选刊 最新文献

Future Virology最新文献

筛选
英文 中文
Friend or foe: association of Euphorbia spp. with Epstein–Barr virus and Burkitt's lymphoma, an in silico approach 朋友或敌人：大戟属与EB病毒和伯基特淋巴瘤的关联，一种计算机方法
IF 3.1 4区 医学
Future Virology Pub Date : 2023-07-07 DOI: 10.2217/fvl-2023-0011
E. Erdag, Ismet Ersalici, Cenk Serhan Ozverel
{"title":"Friend or foe: association of Euphorbia spp. with Epstein–Barr virus and Burkitt's lymphoma, an in silico approach","authors":"E. Erdag, Ismet Ersalici, Cenk Serhan Ozverel","doi":"10.2217/fvl-2023-0011","DOIUrl":"https://doi.org/10.2217/fvl-2023-0011","url":null,"abstract":"Aim: Epstein–Barr virus-related Burkitt's lymphoma (BL) is characterized by EBNA1 expression. Previous studies have hypothesized a correlation between Burkitt's lymphoma and endemicity of Euphorbia spp. whereas others have suggested it possesses antiviral activity. We aimed to investigate the effect of Euphorbia spp. on BL. Methods: AutoDock Vina, GROMACS 2020.4 and VEGA-QSAR were used for in silico assessments. Results: Daphnoretin had a higher binding affinity than the EBNA1 inhibitor VK0044, maintained a steady ligand RMSD value and displayed the largest negative binding energy at the EBNA1 active site. Conclusion: Daphnoretin, a phytochemical of Euphorbia spp., had superior inhibitory activity of EBNA1 over other tested chemicals, suggesting it is an effective therapeutic drug candidate.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2023-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46463402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correlation analysis of HHV-6A viral load and anti-TPO antibody levels in patients with Hashimoto's thyroiditis 桥本甲状腺炎患者HHV-6A病毒载量与抗tpo抗体水平的相关性分析
IF 3.1 4区 医学
Future Virology Pub Date : 2023-07-07 DOI: 10.2217/fvl-2022-0194
Noorossadat Seyyedi, Fariba Esfandiyari, Gholamreza Rafiei Dehbidi, A. Farhadi, F. Zare, S. Namdari, Golrokh Bahmani, Banafsheh Rastegari, Farzaneh Zarghampoor, A. Behzad-Behbahani
{"title":"Correlation analysis of HHV-6A viral load and anti-TPO antibody levels in patients with Hashimoto's thyroiditis","authors":"Noorossadat Seyyedi, Fariba Esfandiyari, Gholamreza Rafiei Dehbidi, A. Farhadi, F. Zare, S. Namdari, Golrokh Bahmani, Banafsheh Rastegari, Farzaneh Zarghampoor, A. Behzad-Behbahani","doi":"10.2217/fvl-2022-0194","DOIUrl":"https://doi.org/10.2217/fvl-2022-0194","url":null,"abstract":"Aim: This study investigated the correlation between anti-thyroid peroxidase (anti-TPO) antibody levels and human herpesvirus 6 (HHV-6) viral load as triggers for Hashimoto's thyroiditis (HT). Materials & methods: The study included 60 HT patients, 60 patients with non-autoimmune thyroid disease, and 60 subjects with normal thyroid function. HHV-6 viral loads in serum samples were detected using real-time PCR. Results: A significant correlation was found between the increase in viral load and increased levels of anti-TPO antibodies in serum samples from HT patients (p = 0.001). Conclusion: The aim of this study was to explore the potential involvement of HHV-6A in the onset of HT, with the goal of identifying improved treatment options for affected individuals.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2023-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48157034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effectiveness and safety of darunavir/cobicistat/emtricitabine/tenofovir alafenamide therapy in an observational Italian cohort: the DIAMANTE study 达芦那韦/柯比司他/恩曲他滨/替诺福韦艾拉酚胺治疗在意大利观察性队列中的有效性和安全性：DIAMANTE研究
IF 3.1 4区 医学
Future Virology Pub Date : 2023-06-22 DOI: 10.2217/fvl-2023-0065
A. Antinori, A. Vergori, D. Ripamonti, D. Valenti, G. Rizzardini, M. Cossu, S. Rusconi, V. Esposito, A. Cascio, G. Orofino, M. Andreoni, E. Manzillo, A. Castagna, D. Mancusi, R. Termini, Marianna Portaro, A. Uglietti
{"title":"Effectiveness and safety of darunavir/cobicistat/emtricitabine/tenofovir alafenamide therapy in an observational Italian cohort: the DIAMANTE study","authors":"A. Antinori, A. Vergori, D. Ripamonti, D. Valenti, G. Rizzardini, M. Cossu, S. Rusconi, V. Esposito, A. Cascio, G. Orofino, M. Andreoni, E. Manzillo, A. Castagna, D. Mancusi, R. Termini, Marianna Portaro, A. Uglietti","doi":"10.2217/fvl-2023-0065","DOIUrl":"https://doi.org/10.2217/fvl-2023-0065","url":null,"abstract":"Aim: DIAMANTE is a retrospective and prospective, non-interventional, cohort study to describe the effectiveness of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in real clinical practice in Italy. Patients & methods: The study enrolled 246 patients: group 1 included patients treated with a darunavir-based regimen (n = 81); group 2 included patients who received antiretroviral treatment not including darunavir before D/C/F/TAF (n = 43); and group 3 included naive patients (n = 122). Effectiveness was evaluated as the virological response at week 48. Results: The D/C/F/TAF virological response rate was 72.1–78.8% and was obtained despite longer follow-up intervals due to the coronavirus 2019 pandemic. The safety of D/C/F/TAF was good as was the overall patient satisfaction and quality of life. Conclusion: This study confirmed the effectiveness and tolerability of D/C/F/TAF in a real-life setting both in naive and pretreated patients, with and without darunavir. Clinical Trial Registration: NCT03577470 ( ClinicalTrials.gov )","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2023-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41745798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence and genotype distribution of human papillomavirus in 92,932 cases in Shanghai, China 上海市92932例人乳头瘤病毒的流行及基因型分布
IF 3.1 4区 医学
Future Virology Pub Date : 2023-06-16 DOI: 10.2217/fvl-2022-0180
Ya-Ping Hou, Cheng Fan, Qing-Qing Jiang, Lei Wu, Ying Luo
{"title":"Prevalence and genotype distribution of human papillomavirus in 92,932 cases in Shanghai, China","authors":"Ya-Ping Hou, Cheng Fan, Qing-Qing Jiang, Lei Wu, Ying Luo","doi":"10.2217/fvl-2022-0180","DOIUrl":"https://doi.org/10.2217/fvl-2022-0180","url":null,"abstract":"Aim: Human papillomavirus (HPV) is the most common cause of high-grade lesions and carcinogenesis such as cervical intraepithelial neoplasia (CIN) and cervical cancer (CC). The prevalence and genotype distribution of HPV infection varies greatly in different geographical areas. Patients & methods: This study enrolled 92,932 patients from January 2017 to December 2021 and analyzed the prevalence and distribution of HPV genotypes. Results: 18038 (19.41%) specimens were HPV-positive. No significant difference in infection rates between men and women (19.05 vs 19.41%). The most prevalent HPV subtypes are HPV52, HPV58, HPV16, HPV53, HPV51 and HPV81. Single infection of HPV has dominated in HPV-positive patients. Conclusion: Our results show that the prevalence and distribution of HPV subtypes have obvious region-specific and age-specific characteristics.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2023-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42220904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between human Epstein–Barr virus and brain cancer: a systematic review and meta-analysis 人类爱泼斯坦-巴尔病毒与脑癌的关系:一项系统综述和荟萃分析
IF 3.1 4区 医学
Future Virology Pub Date : 2023-06-05 DOI: 10.2217/fvl-2022-0219
S. Ghorbani, Vahid Tambrchi, Rana Farzi, A. Khatami, Rahil Nahid Samiei, H. Saadati, M. Noori, Arash Letafati, Atefeh Bahavar, Noorin Hezarpishe, Mehrshid Musavioun, Bahareh Mirzaei, Mohadeseh Sadat Meftagh, Najme Khodaei Doust, Fatemeh Hejami, S. J. Kiani
{"title":"Association between human Epstein–Barr virus and brain cancer: a systematic review and meta-analysis","authors":"S. Ghorbani, Vahid Tambrchi, Rana Farzi, A. Khatami, Rahil Nahid Samiei, H. Saadati, M. Noori, Arash Letafati, Atefeh Bahavar, Noorin Hezarpishe, Mehrshid Musavioun, Bahareh Mirzaei, Mohadeseh Sadat Meftagh, Najme Khodaei Doust, Fatemeh Hejami, S. J. Kiani","doi":"10.2217/fvl-2022-0219","DOIUrl":"https://doi.org/10.2217/fvl-2022-0219","url":null,"abstract":"Aim: The aim of this study was to investigate the pooled prevalence and potential correlation between Epstein–Barr virus (EBV) infection and brain cancers. Materials & methods: We searched for relevant studies in main databases and analyzed the heterogeneity, odds ratio and corresponding 95% CI among all studies using STATA software V.14. Results: Fourteen articles were included in the meta-analysis. The pooled prevalence of EBV among brain cancer patients was 9% (95% CI: 3–16%; I2 = 91.06%). An association was found between EBV and brain cancer (OR: 6.90 [95% CI: 1.81–26.28]; I2 = 0%]). Conclusion: The results of this study indicate a significant association between EBV infection and brain cancer, suggesting EBV infection is a potential risk factor for brain cancer development.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2023-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46701399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Expression of TRIM56 gene in SARS-CoV-2 variants and its relationship with progression of COVID-19. TRIM56基因在SARS-CoV-2变异株中的表达及其与新冠肺炎进展的关系
IF 3.1 4区 医学
Future Virology Pub Date : 2023-06-01 Epub Date: 2023-07-13 DOI: 10.2217/fvl-2022-0210
Rezvan Tavakoli, Pooneh Rahimi, Mojtaba Hamidi-Fard, Sana Eybpoosh, Delaram Doroud, Iraj Ahmadi, Enayat Anvari, Mohammadreza Aghasadeghi, Abolfazl Fateh
{"title":"Expression of <i>TRIM56</i> gene in SARS-CoV-2 variants and its relationship with progression of COVID-19.","authors":"Rezvan Tavakoli, Pooneh Rahimi, Mojtaba Hamidi-Fard, Sana Eybpoosh, Delaram Doroud, Iraj Ahmadi, Enayat Anvari, Mohammadreza Aghasadeghi, Abolfazl Fateh","doi":"10.2217/fvl-2022-0210","DOIUrl":"10.2217/fvl-2022-0210","url":null,"abstract":"<p><strong>Aim: </strong>The present study aimed to determine a correlation between differential <i>TRIM56</i> expression levels and severe infections of COVID-19 between the Alpha, Delta and Omicron BA.5 variants.</p><p><strong>Materials & methods: </strong>This study was performed on 330 COVID-19 patients, including 142 with severe and 188 with mild infections, as well as 160 healthy controls. The levels of <i>TRIM56</i> gene expression were determined using a qPCR.</p><p><strong>Results: </strong><i>TRIM56</i> gene showed significantly lower mRNA expression in the severe and mild groups compared with healthy individuals. Our finding indicated the high and low reduction of <i>TRIM56</i> mRNA expression in Delta and Omicron BA.5 variant, respectively.</p><p><strong>Conclusion: </strong>Further research is needed to characterize the impact of TRIM proteins on the severity of COVID-19.</p>","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348059/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41610222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Design and generation of mRNAs encoding conserved regions of SARS-CoV-2 ORF1ab for T cell-mediated immune activation. 编码用于T细胞介导的免疫激活的严重急性呼吸系统综合征冠状病毒2型ORF1ab保守区的mRNA的设计和产生
IF 3.1 4区 医学
Future Virology Pub Date : 2023-06-01 Epub Date: 2023-06-24 DOI: 10.2217/fvl-2023-0066
Cao Minh Nguyen, Bac An Luong, Thu Thuy Thi Tran, Hoai Nghia Nguyen, Le Son Tran
{"title":"Design and generation of mRNAs encoding conserved regions of SARS-CoV-2 ORF1ab for T cell-mediated immune activation.","authors":"Cao Minh Nguyen, Bac An Luong, Thu Thuy Thi Tran, Hoai Nghia Nguyen, Le Son Tran","doi":"10.2217/fvl-2023-0066","DOIUrl":"10.2217/fvl-2023-0066","url":null,"abstract":"<p><strong>Aim: </strong>To generate mRNAs encoding conserved regions within SARS-CoV-2 ORF1ab which can induce strong T-cell responses to overcome the immune invasion of newly emergent variants.</p><p><strong>Methods: </strong>We selected two conserved regions with a high density of T-cell epitopes using immunoinformatics for mRNA synthesis. The ability of testing mRNAs to activate T cells for IFN-γ production was examined by an ELISpot assay and flow cytometry.</p><p><strong>Results: </strong>Two synthesized mRNAs were successfully translated in MDA-MB-231 cells and had comparable potency to the spike mRNA to induce CD4<sup>+</sup> and CD8<sup>+</sup> T-cell responses in peripheral blood mononuclear cells in 29 out of 34 participants.</p><p><strong>Conclusion: </strong>This study provides a proof-of-concept for the use of SARS-CoV-2 conserved regions to develop booster vaccines capable of eliciting T-cell-mediated immunity.</p>","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308627/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41779498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phase II study of bemnifosbuvir in high-risk participants in a hospital setting with moderate COVID-19. 在患有中度新冠肺炎的医院环境中，贝姆尼福布韦对高危参与者的II期研究
IF 3.1 4区 医学
Future Virology Pub Date : 2023-06-01 Epub Date: 2023-06-23 DOI: 10.2217/fvl-2023-0064
Arantxa Horga, Daniel R Kuritzkes, John J Kowalczyk, Keith Pietropaolo, Bruce Belanger, Kai Lin, Kristen Perkins, Janet Hammond
{"title":"Phase II study of bemnifosbuvir in high-risk participants in a hospital setting with moderate COVID-19.","authors":"Arantxa Horga, Daniel R Kuritzkes, John J Kowalczyk, Keith Pietropaolo, Bruce Belanger, Kai Lin, Kristen Perkins, Janet Hammond","doi":"10.2217/fvl-2023-0064","DOIUrl":"10.2217/fvl-2023-0064","url":null,"abstract":"<p><strong>Background: </strong>Bemnifosbuvir, a novel, oral, nonmutagenic, nonteratogenic nucleotide analogue inhibits SARS-CoV-2 replication <i>in vitro</i>.</p><p><strong>Materials & methods: </strong>Adults in hospital settings with moderate COVID-19 were randomized 1:1 bemnifosbuvir/placebo. Study amended to two parts after interim analysis; part B enrollment limited owing to evolving standard of care.</p><p><strong>Results: </strong>Although the study ended early and did not meet the primary efficacy end point, bemnifosbuvir was well tolerated and did not contribute to all-cause mortality. Compared with placebo, bemnifosbuvir treatment resulted in 0.61 log<sub>10</sub> greater viral load mean change on day 2; trend sustained through day 8. Treatment-emergent adverse events were similar in both groups; most were mild/moderate, unrelated to study drug.</p><p><strong>Conclusion: </strong>Our results suggest a potential role for bemnifosbuvir in blunting COVID-19 progression.</p><p><strong>Clinical trial registration: </strong>NCT04396106 (ClinicalTrials.gov).</p>","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308776/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42780620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Beyond vaccination: prognostic value of p16-HPV testing in squamous cell cervical cancer 除疫苗接种外：p16-HPV检测在癌症鳞状细胞中的预后价值
IF 3.1 4区 医学
Future Virology Pub Date : 2023-05-23 DOI: 10.2217/fvl-2023-0074
Z. Dahbi
{"title":"Beyond vaccination: prognostic value of p16-HPV testing in squamous cell cervical cancer","authors":"Z. Dahbi","doi":"10.2217/fvl-2023-0074","DOIUrl":"https://doi.org/10.2217/fvl-2023-0074","url":null,"abstract":"","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2023-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47604747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of nanotechnology in overcoming barriers to phage therapy: an overview 纳米技术在克服噬菌体治疗障碍中的作用：综述
IF 3.1 4区 医学
Future Virology Pub Date : 2023-05-22 DOI: 10.2217/fvl-2022-0229
Mehrdad Mohammadi, Mehrisadat Mirabadi, Masoumeh Beig, Somaieh Nasereslami, Mina Yazdanmehr, Fatemeh Monfared
{"title":"The role of nanotechnology in overcoming barriers to phage therapy: an overview","authors":"Mehrdad Mohammadi, Mehrisadat Mirabadi, Masoumeh Beig, Somaieh Nasereslami, Mina Yazdanmehr, Fatemeh Monfared","doi":"10.2217/fvl-2022-0229","DOIUrl":"https://doi.org/10.2217/fvl-2022-0229","url":null,"abstract":"Phage treatment has again risen in popularity due to the rise of antibiotic resistance and the need for more reliable alternatives. Human approval of phage therapy has been delayed despite several promising investigations, so, in order to break into the clinical market, existing barriers must be eliminated, and new solutions must be developed. As such, nanotechnology has the potential to help phage formulations overcome their pharmacological drawbacks. The use of nanotechnology to improve phage therapy has received surprisingly little attention in the literature. The key method for increasing phage stability and retention inside the body is encapsulation. New developments in phage therapy using nanotechnology are summarized in this paper.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2023-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43807882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信